miR‐130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Cytopathology

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncy.21869PMID 28449331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Young investigator challenge: MicroRNA‐21/MicroRNA‐126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology

  2016cited by this paper
• WHO classification of tumours of the lung, pleura, thymus and heart

  2015cited by this paper
• Guidelines for the cytopathologic diagnosis of epithelioid and mixed‐type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology

  2015cited by this paper
• Lumican Is Overexpressed in Lung Adenocarcinoma Pleural Effusions

  2015cited by this paper
• YAP immunoreactivity is directly related to pilomatrixoma size and proliferation rate

  2015cited by this paper
• A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis

  2015cited by this paper
• An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers

  2015cited by this paper
• A 4‐MicroRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears

  2014cited by this paper
• Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions

  2014cited by this paper
• Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas.

  2014cited by this paper
• Molecular Pathways Molecular Pathways : YAP and TAZ Take Center Stage in Organ Growth and Tumorigenesis

  2013cited by this paper
• Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

  2013cited by this paper
• Claudin-4 as a Marker for Distinguishing Malignant Mesothelioma From Lung Carcinoma and Serous Adenocarcinoma

  2013cited by this paper
• Detection of MicroRNAs in Archival Cytology Urine Smears

  2013cited by this paper
• miR-1 induces growth arrest and apoptosis in malignant mesothelioma.

  2013cited by this paper
• CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.

  2013cited by this paper
• Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.

  2013cited by this paper
• TGF-b synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth

  2012cited by this paper
• TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth

  2012cited by this paper
• The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies

  2012cited by this paper
• YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes

  2012cited by this paper
• Epithelial–mesenchymal transition in malignant mesothelioma

  2012influential reference
• Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling.

  2011cited by this paper
• LATS2 is a tumor suppressor gene of malignant mesothelioma.

  2011cited by this paper
• Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation

  2011cited by this paper
• Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.

  2010cited by this paper
• A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.

  2010cited by this paper
• MicroRNAs in Cancer.

  2009cited by this paper
• MOC-31 Exhibits Superior Reactivity Compared With Ber-EP4 in Invasive Lobular and Ductal Carcinoma of the Breast: A Tissue Microarray Study

  2009cited by this paper
• BRB-ArrayTools Data Archive for Human Cancer Gene Expression: A Unique and Efficient Data Sharing Resource

  2008cited by this paper
• Novel marker D2‐40, combined with calretinin, CEA, and TTF‐1

  2007cited by this paper
• Novel marker D2-40, combined with calretinin, CEA, and TTF-1 : an optimal set of immunodiagnostic markers for pleural mesothelioma

  2007cited by this paper
• h-Caldesmon, a Useful Positive Marker in the Diagnosis of Pleural Malignant Mesothelioma, Epithelioid Type

  2006cited by this paper
• Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data

  2006cited by this paper
• Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma

  2004cited by this paper
• A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

  2003cited by this paper
• The European mesothelioma epidemic

  1999cited by this paper
• Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.

  1989cited by this paper

• 外泌体来源的circRNA_051778在肺腺癌性恶性胸腔积液和结核性胸腔积液中的表达及作用研究

  2024cites this paper
• Optimal isolation of extracellular vesicles from pleural fluid and profiling of their microRNA cargo

  2023influential citation
• Recommendations for Cell-free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

  2023cites this paper
• Melodic maestros: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of malignant pleural mesothelioma.

  2023cites this paper
• Diagnostic mesothelioma biomarkers in effusion cytology

  2021cites this paper
• The International System for Serous Fluid Cytopathology

  2020cites this paper
• Molecular testing on serous effusions

  2020cites this paper
• Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!

  2020cites this paper
• Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini‐review

  2020cites this paper
• Ancillary Studies for Serous Fluids

  2020cites this paper
• Malignant Mesothelioma: Molecular Markers

  2020cites this paper
• MicroRNA profiling in serous cavity specimens: Diagnostic challenges and new opportunities

  2019cites this paper
• MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions

  2019cites this paper
• Deregulation of small non-coding RNAs in response to environmental carcinogens and during human development

  2019cites this paper
• MicroRNAs – novel biomarkers for malignant pleural effusions

  2019cites this paper
• From “Junk DNA” to Clinically Relevant Tools for Cancer Diagnosis, Staging, and Tailored Therapies: The Incredible Case of Non-Coding RNAs

  2019influential citation
• Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma

  2018cites this paper
• MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review

  2018cites this paper
• ERS/EACTS statement on the management of malignant pleural effusions

  2018cites this paper
• ERS/EACTS statement on the management of malignant pleural effusions

  2018cites this paper
• Circulating Exosomal miR-27a and miR-130a Act as Novel Diagnostic and Prognostic Biomarkers of Colorectal Cancer

  2018cites this paper
• Upregulation of circulating miR130a is correlated with development of Barrett’s esophagus and esophageal adenocarcinoma

  2018cites this paper